Jingjing Li

Title: Innovations by Jingjing Li in Melanoma Research

Introduction

Jingjing Li is an accomplished inventor based in Lexington, MA (US). She has made significant contributions to the field of melanoma research, holding 2 patents that focus on innovative methods for identifying and treating this serious condition. Her work is vital in advancing the understanding and management of melanoma.

Latest Patents

One of her latest patents is titled "Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms." This invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma. It provides a variety of PD-L1 isoform biomarkers, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers are associated with melanoma status. Another significant patent is "Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses." This invention is based on the identification of novel biomarkers predictive of responsiveness to a combination of anti-immune checkpoint and anti-angiogenesis therapies.

Career Highlights

Jingjing Li is affiliated with the Dana-Farber Cancer Institute Inc., where she continues her research and development efforts. Her work is recognized for its potential impact on melanoma treatment and patient outcomes.

Collaborations

Some of her notable coworkers include F Stephen Hodi and Xinqi Wu, who collaborate with her on various research projects aimed at improving melanoma therapies.

Conclusion

Jingjing Li's innovative contributions to melanoma research through her patents and collaborations highlight her commitment to advancing medical science. Her work is essential in the ongoing fight against melanoma, providing new avenues for treatment and patient care.